Febuxostat Use and Dosage in Gout Management

Indications for Febuxostat

The American College of Rheumatology recommends febuxostat as a second-line urate-lowering therapy in patients with gout who have contraindications, intolerance, or inadequate response to allopurinol, starting at 40 mg/day and titrating up to 80 mg/day if needed to achieve target serum urate levels 1, 2
Febuxostat is particularly useful in patients with moderate-to-severe chronic kidney disease (CKD stage ≥3) as it does not require dosage adjustment in this population, unlike allopurinol 1
The American College of Rheumatology suggests that febuxostat should be considered after an appropriate trial of allopurinol, which remains the preferred first-line agent for urate-lowering therapy (ULT) due to its efficacy, safety, and lower cost 1, 2
Febuxostat is not indicated for the treatment of asymptomatic hyperuricemia 2, 3

The recommended starting dose of febuxostat is 40 mg once daily to reduce the risk of gout flares associated with ULT initiation 4, 5
Always initiate concomitant anti-inflammatory prophylaxis (colchicine, NSAIDs, or prednisone) for 3-6 months when starting febuxostat to prevent gout flares 4, 6

The goal of therapy is to achieve and maintain serum urate levels below 6 mg/dL at minimum, and often below 5 mg/dL in patients with severe gout (tophi, chronic arthropathy, frequent attacks) 7, 8
Regular monitoring of serum urate levels is recommended to ensure target levels are achieved and maintained 8, 3

Monitor serum urate levels regularly to ensure target levels are achieved and maintained 8, 3

Consider febuxostat in patients who belong to high-risk groups for allopurinol hypersensitivity syndrome (e.g., Koreans with stage 3 or worse CKD, and those of Han Chinese and Thai descent who test positive for HLA-B*5801) 9, 7
Febuxostat is not recommended as first-line therapy in most patients due to higher cost and the availability of other effective options 1, 2

Failing to provide anti-inflammatory prophylaxis when initiating febuxostat, which can lead to increased gout flares 4, 6
Starting with too high a dose, which increases the risk of flares; always start with 40 mg/day 4, 5
Not monitoring serum urate levels to ensure target levels are achieved 8, 3
Using febuxostat as first-line therapy when allopurinol would be appropriate 1, 2
Discontinuing therapy prematurely when target urate levels are achieved; ULT should be maintained lifelong to prevent recurrence 8, 3